Prognostic Impact of Histologic Grade for Papillary Thyroid Carcinoma.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
22
02
2020
accepted:
28
07
2020
pubmed:
19
8
2020
medline:
11
5
2021
entrez:
19
8
2020
Statut:
ppublish
Résumé
While numerous factors affect prognosis in papillary thyroid carcinoma (PTC), the comparative impact of histologic grade has not been well described. Moreover, indications for external beam radiation therapy (EBRT) remain imprecise. We evaluate clinicopathologic characteristics and outcomes for PTC stratified by grade. We profiled histologic grade for PTC (well differentiated, moderately differentiated, poorly differentiated) via hospital (National Cancer Database) and population-based (Surveillance, Epidemiology, and End Results) registries. Cox regression was used to adjust for clinicopathologic covariates. Statistical interactions between subtypes and the effect of EBRT on survival were assessed. Collectively, worsening clinicopathologic factors (age, tumor size, extrathyroidal extension, nodal spread, M1 disease) and outcomes (disease-free survival, overall survival) correlated with less differentiated state, across all histologic grades (p < 0.001). Multivariable analysis showed escalating hazard with loss of differentiation relative to well-differentiated PTC (moderately differentiated hazard ratio [HR] 1.21, 95% confidence interval [CI] 1.04-1.41, p = 0.02; poorly differentiated HR 2.62, 95% CI 2.23-3.08, p < 0.001). Correspondingly, greater survival benefit was associated with EBRT for poorly differentiated cases (HR 0.36, 95% CI 0.18-0.72, p = 0.004). This finding was upheld after landmark analysis to address potential immortal time bias (HR 0.37, 95% CI 0.17-0.80, p = 0.01). Worsening histologic grade in PTC is independently associated with parallel escalation in mortality risk, on a scale approximating or surpassing established thyroid cancer risk factors. On preliminary analysis, EBRT was associated with improved survival in the most aggressive or least differentiated subvariants. Further investigation is warranted to examine the efficacy of EBRT for select poorly differentiated thyroid carcinomas.
Sections du résumé
BACKGROUND
BACKGROUND
While numerous factors affect prognosis in papillary thyroid carcinoma (PTC), the comparative impact of histologic grade has not been well described. Moreover, indications for external beam radiation therapy (EBRT) remain imprecise. We evaluate clinicopathologic characteristics and outcomes for PTC stratified by grade.
METHODS
METHODS
We profiled histologic grade for PTC (well differentiated, moderately differentiated, poorly differentiated) via hospital (National Cancer Database) and population-based (Surveillance, Epidemiology, and End Results) registries. Cox regression was used to adjust for clinicopathologic covariates. Statistical interactions between subtypes and the effect of EBRT on survival were assessed.
RESULTS
RESULTS
Collectively, worsening clinicopathologic factors (age, tumor size, extrathyroidal extension, nodal spread, M1 disease) and outcomes (disease-free survival, overall survival) correlated with less differentiated state, across all histologic grades (p < 0.001). Multivariable analysis showed escalating hazard with loss of differentiation relative to well-differentiated PTC (moderately differentiated hazard ratio [HR] 1.21, 95% confidence interval [CI] 1.04-1.41, p = 0.02; poorly differentiated HR 2.62, 95% CI 2.23-3.08, p < 0.001). Correspondingly, greater survival benefit was associated with EBRT for poorly differentiated cases (HR 0.36, 95% CI 0.18-0.72, p = 0.004). This finding was upheld after landmark analysis to address potential immortal time bias (HR 0.37, 95% CI 0.17-0.80, p = 0.01).
CONCLUSIONS
CONCLUSIONS
Worsening histologic grade in PTC is independently associated with parallel escalation in mortality risk, on a scale approximating or surpassing established thyroid cancer risk factors. On preliminary analysis, EBRT was associated with improved survival in the most aggressive or least differentiated subvariants. Further investigation is warranted to examine the efficacy of EBRT for select poorly differentiated thyroid carcinomas.
Identifiants
pubmed: 32808161
doi: 10.1245/s10434-020-09023-2
pii: 10.1245/s10434-020-09023-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1731-1739Subventions
Organisme : Levy Family Fellowship in Thyroid Cancer
ID : 001
Organisme : Donna and Jesse Garber Award for Cancer Research
ID : 001
Références
Lin JS, Bowles EJA, Williams SB, Morrison CC. Screening for thyroid cancer: updated evidence report and systematic review for the US preventive services task force. JAMA. 2017;317(18):1888–903.
pubmed: 28492904
Force USPST, Bibbins-Domingo K, Grossman DC, et al. Screening for thyroid cancer: US preventive services task force recommendation statement. JAMA. 2017;317(18):1882–1887.
Ho AS, Davies L, Nixon IJ, et al. Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates. Cancer. 2015;121(11):1793–9.
pubmed: 25712809
pmcid: 4923938
Ho AS, Luu M, Zalt C, et al. Mortality risk of nonoperative papillary thyroid carcinoma: a corollary for active surveillance. Thyroid. 2019;29:1409–1417.
pubmed: 31407637
pmcid: 7476400
Ho AS, Chen I, Melany M, Sacks WL. Evolving management considerations in active surveillance for micropapillary thyroid carcinoma. Curr Opin Endocrinol Diabetes Obes. 2018;25(5):353–9.
pubmed: 30153222
Ho AS, Daskivich TJ, Sacks WL, Zumsteg ZS. Parallels between low-risk prostate cancer and thyroid cancer: a review. JAMA Oncol. 2019;5(4):556–64.
pubmed: 30543358
Walgama E, Sacks WL, Ho AS. Papillary thyroid microcarcinoma: optimal management versus overtreatment. Curr Opin Oncol. 2020;32(1):1–6.
pubmed: 31633497
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.
pubmed: 26462967
pmcid: 26462967
Tam S, Amit M, Boonsripitayanon M, et al. Adjuvant external beam radiotherapy in locally advanced differentiated thyroid cancer. JAMA Otolaryngol Head Neck Surg. 2017;143(12):1244–51.
pubmed: 29098272
pmcid: 5824297
Ho AS, Luu M, Barrios L, et al. Incidence and mortality risk spectrum across aggressive variants of papillary thyroid carcinoma. JAMA Oncol. 2020;6:706.
pubmed: 32134428
Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102(6):1088–95.
pubmed: 3686348
Akslen LA. Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer. 1993;72(9):2680–5.
pubmed: 8402490
Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery. 1994;116(6):1036–40; discussion 1040-1.
pubmed: 7985084
Baskar R, Dai J, Wenlong N, Yeo R, Yeoh KW. Biological response of cancer cells to radiation treatment. Front Mol Biosci. 2014;1:24.
pubmed: 25988165
pmcid: 4429645
Beckham TH, Romesser PB, Groen AH, et al. Intensity-modulated radiation therapy with or without concurrent chemotherapy in nonanaplastic thyroid cancer with unresectable or gross residual disease. Thyroid. 2018;28(9):1180–9.
pubmed: 30105947
pmcid: 6154443
Chow SM, Law SC, Mendenhall WM, et al. Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys. 2002;52(3):784–95.
pubmed: 11849802
Kiess AP, Agrawal N, Brierley JD, et al. External-beam radiotherapy for differentiated thyroid cancer locoregional control: a statement of the American Head and Neck Society. Head Neck. 2016;38(4):493–8.
pubmed: 26716601
Haddad RI, Nasr C, Bischoff L, et al. NCCN guidelines insights: thyroid carcinoma, Version 2.2018. J Natl Compr Cancer Netw. 2018;16(12):1429–40.
Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017;3(12):1722–8.
pubmed: 28241198
Venables WN, Ripley BD. Modern Applied Statistics with S. 4th ed. Berlin: Springer; 2002.
Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515–26.
Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189–94.
pubmed: 18032770
Ho AS, Kim S, Tighiouart M, et al. Quantitative survival impact of composite treatment delays in head and neck cancer. Cancer. 2018;124(15):3154–62.
pubmed: 29742280
pmcid: 6097917
Team RC. R: a language and environment for statistical computing. 2018; https://www.R-project.org/ . Accessed 1 June 2020.
Michels JJ, Jacques M, Henry-Amar M, Bardet S. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol. 2007;38(2):212–9.
pubmed: 17097131
Morris LG, Shaha AR, Tuttle RM, Sikora AG, Ganly I. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid. 2010;20(2):153–8.
pubmed: 20151822
pmcid: 3714453
Kuo EJ, Goffredo P, Sosa JA, Roman SA. Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. Thyroid. 2013;23(10):1305–11.
pubmed: 23600998
pmcid: 3783926
Regalbuto C, Malandrino P, Frasca F, et al. The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes. J Endocrinol Invest. 2013;36(4):249–54.
pubmed: 22776915
Regalbuto C, Malandrino P, Tumminia A, Le Moli R, Vigneri R, Pezzino V. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. Thyroid. 2011;21(4):383–9.
pubmed: 21309722
Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive variants of papillary thyroid carcinoma. Head Neck. 2011;33(7):1052–9.
pubmed: 20824810
Akslen LA, LiVolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer. 2000;88(8):1902–8.
pubmed: 10760768
Mete OS, Asa SL, Bullock MJ, Carty SE, Hodak SP, McHugh JB, Nikiforov YE, Pettus J, Richardson MS, Shah J, Thompson LD. Protocol for the examination of specimens from patients with carcinomas of the thyroid gland. Northfield: College of American Pathologists; 2019.
Lee N, Tuttle M. The role of external beam radiotherapy in the treatment of papillary thyroid cancer. Endocr Relat Cancer. 2006;13(4):971–7.
pubmed: 17158749
Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 1998;82(2):375–88.
pubmed: 9445196
Farahati J, Reiners C, Stuschke M, et al. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer. 1996;77(1):172–80.
pubmed: 8630926
Biermann M, Pixberg M, Riemann B, et al. Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer—results after 874 patient-years of follow-up in the MSDS-trial. Nuklearmedizin. 2009;48(3):89–98; quiz N15.
pubmed: 19322503
Terezakis SA, Lee KS, Ghossein RA, et al. Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2009;73(3):795–801.
pubmed: 18676097
Romesser PB, Sherman EJ, Shaha AR, et al. External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. J Surg Oncol. 2014;110(4):375–82.
pubmed: 24961938
Brierley J, Tsang R, Panzarella T, Bana N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf). 2005;63(4):418–27.
Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31(8):1256–64.
pubmed: 17667551
Hiltzik D, Carlson DL, Tuttle RM, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer. 2006;106(6):1286–95.
pubmed: 16470605
Sanders EM, Jr., LiVolsi VA, Brierley J, Shin J, Randolph GW. An evidence-based review of poorly differentiated thyroid cancer. World J Surg. 2007;31(5):934–45.
pubmed: 17431717
Ibrahimpasic T, Ghossein R, Carlson DL, et al. Outcomes in patients with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2014;99(4):1245–52.
pubmed: 24512493
Burman KD. Is poorly differentiated thyroid cancer poorly characterized? J Clin Endocrinol Metab. 2014;99(4):1167–9.
pubmed: 24702015
Ibrahimpasic T, Ghossein R, Shah JP, Ganly I. Poorly differentiated carcinoma of the thyroid gland: current status and future prospects. Thyroid. 2019;29(3):311–21.
pubmed: 30747050
pmcid: 6437626
Epstein JI. Prostate cancer grading: a decade after the 2005 modified system. Mod Pathol. 2018;31(S1):S47–63.
pubmed: 29297487
Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12(4):207.
pubmed: 20804570
pmcid: 2949637
Geetha KM, Leeky M, Narayan TV, Sadhana S, Saleha J. Grading of oral epithelial dysplasia: points to ponder. J Oral Maxillofac Pathol. 2015;19(2):198–204.
pubmed: 26604497
pmcid: 4611929